BioWorld

Jan. 30, 2004

View Archived Issues

Biogen Idec's Antegren Positive In Maintenance Trial For Crohn's

Despite a failed trial last year, Antegren now has garnered some positive Phase III data, meeting its primary endpoint by maintaining a response in Crohn's disease patients. (BioWorld Today) Read More

MedImmune Revenues Top $1B As Firm Sorts FluMist Options

Read More

Labopharm Reports Mixed Data For Tramadol, Plans NDA Filing

Read More

Chiron Earnings Rise Due To Vaccine, Other Product Growth

Read More

Other News To Note

Read More

Appointments And Advancements

Read More